PUBLISHER: Grand View Research | PRODUCT CODE: 1750670
PUBLISHER: Grand View Research | PRODUCT CODE: 1750670
The global structural heart occlusion devices market size was estimated at USD 4.0 billion in 2024 and is projected to grow at a CAGR of 7.0% from 2025 to 2030. The structural heart occlusion devices market is advancing due to the rising burden of structural heart diseases, increasing acceptance of minimally invasive therapies, and favorable regulatory and reimbursement changes. Growing clinical awareness and procedural innovations are expanding the eligible patient pool, reinforcing a strong positive growth outlook.
The increasing prevalence of structural heart diseases is a major driver for the structural heart occlusion devices market. Conditions such as atrial septal defects, patent foramen ovale, and left atrial appendage abnormalities are gaining greater clinical attention as diagnostic technologies continue to advance. The American Heart Association's 2024 Statistical Update projects that the prevalence of atrial fibrillation (AF) in the U.S. will rise from approximately 5.2 million in 2010 to 12.1 million by 2030, underscoring the growing clinical need for effective interventions. As awareness improves and diagnostic pathways become more standardized, the addressable patient population for occlusion therapies is expanding significantly, creating a strong foundation for market growth.
As the prevalence of atrial fibrillation (AF) continues to rise globally, Left Atrial Appendage Occlusion (LAAO) procedures are gaining traction within the Structural Heart Occlusion Devices market. LAAO offers a non-pharmacologic alternative to oral anticoagulants for stroke prevention in patients with non-valvular AF, particularly those at high bleeding risk. A February 2025 article published in the European Heart Journal Supplements focused on the growing adoption of LAAO for patients with contraindications to long-term oral anticoagulant therapy (OAT). The article emphasizes that despite OAT's role in stroke prevention, certain patients, especially those with a history of bleeding events, remain at high risk for ischemic strokes.
Regulatory and reimbursement initiatives are playing an increasingly important role in shaping the structural heart occlusion devices market. Favorable policy environments are essential to encourage clinical adoption, promote investment in innovation, and expand patient access to advanced therapies. In March 2025, the Centers for Medicare & Medicaid Services (CMS) approved the REDUCE-AF clinical trial under Coverage with Evidence Development (CED) to evaluate the LAmbre Plus Left Atrial Appendage Closure System. This decision reflects continued regulatory emphasis on building robust clinical evidence to support device utilization in patients with non-valvular atrial fibrillation.
Global Structural Heart Occlusion Devices Market Report Segmentation
This report forecasts revenue growth at global, regional & country levels and provides an analysis of the industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global structural heart occlusion devices market report based on type, end-use, and region: